

90242\_Auto\_Edited.docx

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 90242

**Manuscript Type:** ORIGINAL ARTICLE

*Prospective Study*

**sTREM-1 as promising prognostic biomarker for acute-on-chronic liver failure and mortality in patients with acute decompensation of cirrhosis**

Value of sTREM-1 in AD patients.

Songman Yu, Hai Li, Guo-Hong Deng, <sup>8</sup>Xian-Bo Wang, Xin Zheng, Jin-Jun Chen, Zhong-Ji Meng, Yu-Bao Zheng, Yan-Hang Gao, Zhi-Ping Qian, Feng Liu, Xiao-Bo Lu, Yu Shi, Jia Shang, Ruo-Chan Chen, Yan Huang

## **Abstract**

### **BACKGROUND**

Acute decompensation (AD) of cirrhosis is associated with high short-term mortality, mainly due to the development of acute-on-chronic liver failure (ACLF). Thus, there is a need for biomarkers for early and accurate identification of AD patients with high risk of development of ACLF and mortality. sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) is released from activated innate immune cells and correlated with various inflammatory processes.

### **AIM**

To explore the prognostic value of sTREM-1 in patients with AD of cirrhosis.

### **METHODS**

A multicenter prospective cohort of 442 patients with cirrhosis hospitalized for AD was divided into a study cohort ( $n = 309$ ) and validation cohort ( $n = 133$ ). Demographic and clinical data were collected, and serum sTREM-1 was measured at admission. All enrolled patients were followed-up for at least 1 year.

### **RESULTS**

In patients with AD and cirrhosis, serum sTREM-1 was an independent prognosis predictor for 1-year survival and correlated with liver, coagulation, cerebral and kidney failure. A new prognostic model of AD (P-AD) incorporating sTREM-1, blood urea nitrogen (BUN), total bilirubin (TBil), international normalized ratio (INR) and hepatic encephalopathy grades was established and performed better than the model for end-stage liver disease (MELD), MELD-sodium (MELD-Na), chronic liver failure-consortium ACLF (CLIF-C ACLF) and CLIF-C AD scores. Additionally, sTREM-1 was increased in ACLF and predicted the development of ACLF during first 28-day follow-up. The ACLF risk score (ACLF-R) incorporating serum sTREM-1, BUN, INR, TBil and aspartate aminotransferase (AST) levels was established and significantly superior to

MELD, MELD-Na, CLIF-C ACLF, CLIF-C AD and P-AD in predicting risk of ACLF development.

## CONCLUSION

Serum sTREM-1 is a promising prognostic biomarker for ACLF development and mortality in patients with AD of cirrhosis.

**Key Words:** Soluble triggering receptor expressed on myeloid cell-1; sTREM-1; Cirrhosis; Acute-on-chronic liver failure; Prognostic biomarker.

Yu S, Li H, Deng GH, Wang XB, Zheng X, Chen JJ, Meng ZJ, Zheng YB, Gao YH, Qian ZP, Liu F, Lu XB, Shi Y, Shang J, Chen RC, Huang Y. sTREM-1 as promising prognostic biomarker for acute-on-chronic liver failure and mortality in patients with acute decompensation of cirrhosis. *World J Gastroenterol* 2023; In press

**Core Tip:** Acute decompensation (AD) of cirrhosis is associated with high short-term mortality, mainly due to development of acute-on-chronic liver failure (ACLF). sTREM-1 (serum soluble triggering receptor expressed on myeloid cells-1) is an independent risk factor for development of ACLF and mortality in patients with AD of cirrhosis. The new prognostic model of AD (P-AD) and the ACLF risk score (ACLF-R) were established and performed better than currently available prognostic models in predicting 1-year mortality and 28-day ACLF development in patients with AD of cirrhosis. Serum sTREM-1 Level, P-AD and ACLF-R score will facilitate clinical decision-making in the management of AD of cirrhosis.

## INTRODUCTION

Acute decompensation (AD) of cirrhosis is acute deterioration of pre-existing cirrhosis.<sup>1</sup> As the disease progresses, a severe syndrome hallmarked by intense systemic inflammatory response, multiorgan failure and high short-term mortality is observed

and defined as acute-on-chronic liver failure (ACLF).<sup>2</sup> The prognosis of AD with or without ACLF is significantly different. Hence, early and accurate biomarkers are required to identify AD patients with a high risk of development of ACLF and mortality, to improve the management and outcomes. Despite extensive research, few biomarkers can satisfactorily solve these challenges.<sup>3,4</sup> Therefore, further investigation is warranted to find novel biomarkers for accurate risk stratification of patients with AD of cirrhosis.

Infections and sepsis contribute to poor prognosis in AD patients with or without ACLF.<sup>1,5</sup> Triggering receptor expressed on myeloid cells-1 (TREM-1) is a pattern recognition receptor (PRR) and member of the immunoglobulin superfamily, which is mainly expressed on the surface of immune cells. TREM-1 is a crucial mediator of bacterial infection and septic shock that acts by synergizing with other PRRs to amplify the inflammatory responses.<sup>6,7</sup> Soluble TREM-1 (sTREM-1), the extracellular portion of TREM-1, is cleaved by metalloproteinases and released during inflammation.<sup>8</sup> sTREM-1 has been explored as a biomarker for the diagnosis and prognosis of bacterial infections and sepsis.<sup>7,9-11</sup>

Previous studies have demonstrated that sTREM-1 has high diagnostic value for sepsis in patients with ACLF.<sup>12</sup> In addition, sTREM-1 Levels perform well in identifying bacterial infection and predicting 90-day mortality for patients with cirrhosis.<sup>13</sup> The value of sTREM-1 as a biomarker in cirrhosis has been evaluated but not extensively. The potential value of sTREM-1 in AD patients is still unknown.

Against the above background, we hypothesized that sTREM-1 has the potential to serve as a biomarker of progression and prognosis in AD of cirrhosis, reflecting the risk of ACLF development. The aim of this study was to investigate the effectiveness of sTREM-1 for the prediction of ACLF development and mortality in patients with AD of cirrhosis. Soluble CD14 subtype (sCD14-ST), another biomarker of sepsis in ACLF found in our previous study,<sup>12</sup> was also assessed for comparison.

## **MATERIALS AND METHODS**

### ***Ethical approval***

This study was approved by the Renji Hospital Ethics Committee of Shanghai Jiao Tong University School of Medicine (ethics codes: (2014)148k) and all of the patients signed written informed consent before the study.

### ***Study population***

Patients with AD of cirrhosis were recruited from a prospective multicenter cohort study, named CATCH-LIFE (NCT02457637), conducted by the Chinese Chronic Liver Failure Consortium, which comprised 15 hospitals from January 2015 to December 2017. All 442 patients were randomly divided into a study cohort (n = 309) and a validation cohort (n = 133) using EXCEL-generated random numbers. The sample size was determined based on the calculation results of the PASS 15.0 and by reference to high-quality literature on similar studies.<sup>4</sup> Exclusion criteria are listed in the Supplemental Methods.

### ***Study design***

Clinical characteristics, candidate indicators and outcomes were collected to develop and validate the novel ACLF risk prediction score and prognostic score for AD of cirrhosis. Serum samples were collected at admission to measure the concentrations of C-reactive protein (CRP), procalcitonin (PCT), sTREM-1 and sCD14-ST using the Luminex 200 System (Millipore). Patients' clinical data and laboratory parameters were collected and recorded at admission (day 1) and during 28-day follow-up (on day 4, 7, 14, 21 and 28). The management of patients with AD was according to established guidelines.<sup>14</sup> Patients were followed-up for at least 1 year. The presence or development of ACLF was carefully evaluated at admission or during the first 28-day after enrollment.

### ***Definitions***

Cirrhosis was diagnosed based on a composite of clinical signs and findings provided by imaging examination or signs of portal hypertension on endoscopy.<sup>15</sup> Patients with cirrhosis who had at least one AD event, including gastrointestinal bleeding, hepatic encephalopathy, ascites, bacterial infection or jaundice [total bilirubin (TBil) > 5 mg/dL], within 1 month before enrollment were diagnosed with AD.<sup>2</sup> The diagnostic criteria of ACLF were based on the CANONIC study.<sup>16</sup>

### *Calculation of scores*

The model for end-stage liver disease (MELD), MELD-sodium (MELD-Na), chronic liver failure-consortium ACLF (CLIF-C ACLF) and CLIF-C AD scores were calculated as detailed in the Supplemental Methods.

### *Statistical analysis*

Statistical analysis was performed using SPSS 26.0, MedCalc 19.0, and R 4.1.1 (<https://www.r-project.org>). Categorical variables, presented as numbers (percentages) in tables, were analyzed by  $\chi^2$  or Fisher's exact test. The normality assumption of continuous variables was validated using the Kolmogorov-Smirnov test. Normally distributed variables were presented as mean  $\pm$  SD and compared using Student's *t* test. Non-normally distributed variables were presented as median (interquartile range, IQR) and compared using the Mann-Whitney *U* test. Rank correlation was analyzed by the Spearman method.

Liver transplanted patients (11 in study cohort; 6 in validation cohort) were excluded from the mortality or ACLF development analysis. Risk factors that were significantly associated with the 1-year mortality or 28-day ACLF development in univariate analysis were selected as candidate variables for the multivariate analysis. Independent prognostic factors for AD were identified by multivariate Cox regression. The proportional hazards assumption was assessed by the Schoenfeld residual test. The prognostic model of AD (P-AD) was developed utilizing multivariate Cox regression analysis according to the stepwise forward method: likelihood ratios, with entry and

removal probabilities of 0.05 and 0.10, respectively. Independent risk factors for predicting ACLF development were identified by multivariate logistic regression. The ACLF risk score (ACLF-R) was developed utilizing multivariate logistic regression analysis according to the stepwise forward method: likelihood ratios, with entry and removal probabilities of 0.05 and 0.10, respectively.

The goodness-of-fit of the new predictive models was evaluated using the Hosmer-Lemeshow test, calibration curve and Brier score. Harrell's C-index, area under the receiver operating curve (AUROC), and the z test (DeLong's method) were used to assess the performance of the new models. The Kaplan-Meier method and log-rank test were used to compare the cumulative survival rates. The cut-point of the "high" and "low" group was based on Youden Index. The performance of the predictive Cox model in the validation cohort was assessed using the same statistical analysis methods applied to the derivation data.  $P < 0.05$  was considered statistically significant.

## **RESULTS**

### ***Characteristics of the study population***

Demographic and clinical characteristics of both study and validation cohorts are listed in Table S1. There were no significant differences in baseline characteristics between both cohorts. Most patients were male (69%) and the most common etiology was HBV infection (63%). About half of patients (41%) had a history of previous decompensation of cirrhosis before admission. Patients had moderate to severe hepatic impairment as reflected by a mean MELD score of 14 and CLIF-C ACLF score of 35.

### ***Relationship between sTREM-1 Levels and mortality***

During a 1-year follow-up period, 112 (25%) patients died and 17 (4%) were transplanted. Univariate analysis of 1-year survival in the study and validation cohort are shown in Tables 1 and S2, respectively. As expected, nonsurvivors had significantly higher levels of TBil and international normalized ratio (INR) reflecting worse liver function. The presence of organ failure (liver, kidney, coagulation and cerebral failure)



was significantly more frequent in nonsurvivors. Nonsurvivors had significantly higher frequency of bacterial infections with higher white blood cell (WBC), CRP and PCT levels. Finally, serum sTREM-1 levels at admission were significantly higher in nonsurvivors (Figures 1A and S1A) with (Figure S1C) or without (Figure S1D) bacterial infection. The cumulative survival duration for patients with low sTREM-1 levels was significantly longer than in those with high sTREM-1 levels (Figure 1D). However, no significant difference was found between the survivors and nonsurvivors in the serum levels of sCD14-ST (Figures 1B and S1B). The AUROC of sTREM-1 for 1-year mortality was 0.724, which was significantly higher than that of sCD14-ST and CRP (AUROC = 0.551 and 0.651 respectively, both  $P < 0.05$ ) and tended to be higher than those of WBC and PCT (AUROC = 0.662 and 0.679,  $P = 0.063$  and 0.109, respectively; Figure 1C and Table S3).

#### *Development and evaluation of sTREM-1 based prognostic model*

Multivariate Cox regression analyses showed that sTREM-1, TBil, INR, blood urea nitrogen (BUN) and hepatic encephalopathy (HE) grades were independent prognostic factors for AD of cirrhosis (Table 1). Therefore, we developed a prognostic model [C-index: 0.796; 95% confidence interval (CI): 0.745–0.846], named P-AD, based on five parameters:  $P\text{-AD} = 0.512 \times \text{HE} + 0.288 \times \ln [\text{TBil (mg/dL)}] + 2.145 \times \ln (\text{INR}) + 0.725 \times \ln [\text{BUN (mmol/L)}] + 0.772 \times \ln [\text{sTREM-1 (}\mu\text{g/L)}]$ , where HE = 0 for patients without HE; HE = 1 for patients with mild HE (grades 1 and 2); and HE = 2 for patients with severe HE (grades 3 and 4).

The P-AD score for the nonsurvivor group was significantly higher in the study (Figure 2A, B) and validation (Figure S2A, B) cohorts. This model had a good discriminatory performance in AD patients with (Figure 2C) or without (Figure S3A) ACLF. In predicting the outcome of AD patients, the P-AD score significantly outperformed MELD, MELD-Na and CLIF-C ACLF scores in the study (Figure 2E and Table S4) and validation (Figure S2C-E and Table S5) cohorts. The P-AD score also showed superiority and improvement in predictive ability in AD patients without

ACLF (Figure S3C, D and Table S6). The calibration curves were well fitted between the predicted and observed survival rate for patients with (Figure 2D) or without (Figure S3B) ACLF. The estimated intercept (95% CI) and slope (95% CI) for the study cohort were -0.036 (-0.190 to 0.118) and 0.993 (0.798–1.189), and for the validation cohort 0.000 (-0.227 to 0.227) and 0.966 (0.673–1.259), respectively. No significant differences from a perfect fit (intercept = 0, slope = 1) were found in either the study ( $P = 0.646$  and  $0.947$ ) or the validation ( $P = 1.000$  and  $0.820$  for intercept and slope, respectively) cohort. The Bier score for the P-AD in study and validation cohorts were 0.107 and 0.121, respectively. For patients without ACLF, the intercept and slope were -0.017 (-0.137 to 0.103) and 0.982 (0.837–1.127) in study cohort, and -0.074 (-0.359 to 0.211) and 1.018 (0.679–1.356) in validation cohort, respectively. Intercepts and slopes were not significantly different from perfect fit in both the study ( $P = 0.781$  and  $0.805$ ) and the validation ( $P = 0.610$  and  $0.917$ ) cohorts. The Bier scores were 0.108 and 0.097 in study and validation cohorts, respectively.

#### ***Relationship between sTREM-1 Levels and ACLF***

We investigated association between serum levels of sTREM-1 or sCD14-ST at admission and the presence of ACLF. Patients with ACLF had significantly higher sTREM-1 baseline levels than those without ACLF in both bacterial infection (BI) and non-BI groups (Figure 3A). sTREM-1 levels increased with numbers of failed organs. In contrast, there was no significant difference in sCD14-ST levels whether grouped by the presence of ACLF (Figure S3E) or by the number of failed organs (Figure 1E). Patients with liver, coagulation, kidney or cerebral failure had significantly higher sTREM-1 Levels than those without (Figure 1F). In contrast, there was no correlation between sCD14-ST and any of the aforementioned organ failures (Figure S1E). To investigate the potential of sTREM-1 as a biomarker for ACLF development, univariate analysis of 28-day ACLF development was performed (Table 2). Patients who developed ACLF during the first 28-day follow-up had significantly higher sTREM-1 Levels at admission.

### *Development and evaluation of sTREM-1-based ACLF prediction model*

The multivariate analysis showed that aspartate aminotransferase (AST), TBil, INR, BUN and sTREM-1 levels were independent factors in the occurrence of ACLF during 28-day follow-up (Table 2). Therefore, we developed an ACLF risk prediction model (Hosmer-Lemeshow test,  $P = 0.811$ ), named ACLF-R, based on:  $\text{ACLF-R} = 1.210 \times \ln [\text{TBil (mg/dL)}] + 0.565 \times \ln [\text{AST (U/L)}] + 3.132 \times \ln (\text{INR}) + 1.131 \times \ln [\text{BUN (mmol/L)}] + 1.237 \times \ln [\text{sTREM-1 (}\mu\text{g/L)}]$ .

The ACLF-R score for patients who developed ACLF during 28-day follow-up was significantly higher than those who did not (Table 2). The ACLF-R score showed greater predictive power for AD patients' 28-day ACLF development than the MELD, MELD-Na, CLIF-C ACLF, CLIF-C AD and P-AD scores (Figure 3B and Table 3). The calibration curve had a good fit between the predicted and observed probabilities of ACLF development (Figure 3C). The estimated intercept (95% CI) and slope (95% CI) were 0.003 (-0.012 to 0.018) and 0.968 (0.889–1.046), and no significant difference from a perfect fit was found ( $P = 0.672$  and  $0.418$  for intercept and slope, respectively). The Bier score for the ACLF-R was 0.062.

## **DISCUSSION**

The development of simple and accurate predictive models permitting the early recognition of individuals with high risk of development of ACLF and mortality could enhance the triage, management, and prognosis of AD patients. In this study, we assessed the performance of sTREM-1 as a disease progression and prognostic biomarker in AD patients and further constructed P-AD and ACLF-R score based on sTREM-1 and four other clinical parameters. Serum sTREM-1 Levels at admission were independently associated with 1-year mortality and 28-day ACLF development in patients with AD of cirrhosis. P-AD and ACLF-R scores outperformed the MELD, MELD-Na, CLIF-C ACLF and CLIF-C AD scores in a multicenter prospective cohort.

Because the pathogenic mechanism of AD, especially ACLF, is complex and involves multiple systems,<sup>1,2</sup> a comprehensive prognostic model with indicators

reflecting multiple pathological processes is required to forecast the prognosis of AD. The MELD score is an accurate predictor of survival in patients with advanced liver disease and used in organ allocation for liver transplantation.<sup>17</sup> MELD-Na, a model incorporating serum sodium into MELD, has been demonstrated to provide more accurate mortality prediction than MELD.<sup>18</sup> Therefore, MELD-Na is the most widely used model for organ allocation in patients listed for liver transplantation. Recent studies showed that patients with cirrhosis with persistently low MELD-Na scores still experienced high rates of liver-related mortality.<sup>19</sup> Patients with ACLF are at a mortality disadvantage in the current MELD-Na based system because MELD-Na does not capture 90-day mortality risk in ACLF.<sup>20</sup> Organ failure based scores such as CLIF-C ACLF perform better than MELD based assessment in predicting waiting list mortality among ACLF patients.<sup>16,21</sup> The CLIF-C AD score was developed for AD patients without ACLF.<sup>1</sup> A recent study showed that even in the low-risk group (CLIF-C ADs  $\leq$  45), the 90-day mortality was as high as 10%.<sup>22</sup> Therefore, it is necessary to enhance prognosis stratification in patients with AD. The present study demonstrated that serum sTREM-1 Levels could act as independent predictor of 1-year mortality in patients with AD of cirrhosis.

sTREM-1 is increased in ACLF patients with sepsis<sup>12</sup> and cirrhotic patients with bacterial infection<sup>13</sup>. sTREM-1 is also increased and involved in noninfectious inflammatory diseases such as relapsing polychondritis<sup>23</sup> and adult-onset Still's disease<sup>24</sup>. Infections and sepsis contribute to poor prognosis in AD patients with or without ACLF.<sup>1,5</sup> Systemic circulatory dysfunction and systemic inflammation are typical pathologies of AD and further exacerbated in ACLF.<sup>25</sup> Therefore, it can be speculated that there are two major theories supporting sTREM-1 as a prognostic biomarker in AD. First, sTREM-1 Levels may reflect bacterial infections and/or sepsis in patients with AD of cirrhosis. Second, sTREM-1 Levels may reflect the severity of systemic inflammatory in AD. Moreover, we developed and validated the P-AD score, based on sTREM-1 and four other parameters (TBil, INR, BUN and HE grade). P-AD score had a better prognostic capability than MELD, MELD-Na, CLIF-C ACLF, and



CLIF-C AD scores. Therefore, the P-AD score enables <sup>2</sup> decision-making regarding the allocation of intensive care resources and priorities of liver transplantation for patients with AD of cirrhosis.

TREM-1 pathways contribute to the pathology of infectious diseases<sup>6-11</sup> and noninfectious inflammatory diseases.<sup>23,24</sup> <sup>7</sup> sTREM-1 is a specific biomarker of TREM-1 pathway activation.<sup>26</sup> Bacterial infection is one of the most common triggers for inflammation promoting ACLF development.<sup>2,27</sup> It can induce inflammation *via* two classes of molecules: pathogen-associated molecular patterns (PAMPs) and virulence factors. Both molecules are recognized by PRRs and result in the production of inflammatory molecules. <sup>5</sup> The inflammatory response to bacteria can be excessive and cause tissue damage, releasing damage-associated molecular patterns (DAMPs). DAMP recognition by PRRs accentuates inflammation and leads to ACLF *via* a storm of inflammatory cytokines.<sup>28</sup> These findings suggest that systemic inflammation can drive ACLF. sTREM-1, a PRR that amplifies inflammatory responses by synergizing with other PRRs, <sup>5</sup> could help define signatures to improve our understanding of inflammation in ACLF and inform preventative strategies. Our findings are consistent with these results and support the hypothesis that increased sTREM-1 Levels may be involved in and reflect the activation of inflammatory pathways occurring in ACLF.

So far, there is a paucity of commonly accepted and verified biomarkers or models to assess the probability of ACLF development. This study revealed that sTREM-1 is significantly increased in ACLF and correlated with failure of critical organs, including liver, brain and kidney, as well as coagulation. Further results revealed that for AD patients without ACLF at admission, sTREM-1 could be a useful biomarker to assess the risk of ACLF development. We developed and validated the ACLF-R score, based on sTREM-1 and four other parameters (TBil, AST, INR and BUN), which have better predictive capability in ACLF developing than MELD, MELD-Na, CLIF-C ACLF, CLIF-C AD, and P-AD scores.

There were some strengths and limitations to the present study. First, this investigation was based on a large multicenter prospective cohort of patients with

cirrhosis hospitalized for AD. Second, results obtained from the study cohort were validated by the validation cohort. However, since the number of AD patients who progressed to ACLF during the 28-day follow-up was limited, our results for sTREM-1 and ACLF-R predicting ACLF development need to be validated in another independent multicenter prospective cohort. Finally, the design of this investigation did not involve a mechanistic demonstration about the role of sTREM-1 in the pathophysiology of ACLF. Therefore, the mechanistic hypothesis suggested by current results needs to be investigated in future studies.

## **CONCLUSION**

Serum sTREM-1 is a promising biomarker to predict development of ACLF and mortality in patients with AD of cirrhosis. The P-AD and ACLF-R score were superior to currently available prognostic models in predicting mortality and development of ACLF.

## **ARTICLE HIGHLIGHTS**

### ***Research background***

Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a biomarker of inflammatory diseases such as liver injury, and is released from activated innate immune cells.

### ***Research motivation***

Acute decompensation (AD) of cirrhosis <sup>1</sup> is associated with high short-term mortality, mainly due to the development of acute-on-chronic liver failure (ACLF). Thus, accurate biomarkers are required to identify AD patients with high risk of ACLF development and mortality.

### ***Research objectives***

This study aimed to explore the prognostic value of sTREM-1 in patients with AD of cirrhosis, and to construct more effective prognostic models for improving patient clinical management and prognosis.

### **Research <sup>3</sup>methods**

We collected data and samples from 442 hospitalized patients with AD of cirrhosis from a multicenter prospective cohort including 15 Liver units in 10 provinces of China. Prognostic model of AD (P-AD) and ACLF risk score (ACLF-R) were established based on independent factors associated with mortality or ACLF development, and compared with widely used scores, such as <sup>6</sup>model for end-stage liver disease (MELD), MELD-sodium (MELD-Na), chronic liver failure-consortium ACLF (CLIF-C ACLF) and CLIF-C AD.

### **Research results**

Serum sTREM-1 Level was associated with 1-year mortality and correlated with organ failure, including liver, coagulation, kidney, and cerebral failures, in patients with AD of cirrhosis. Serum sTREM-1 was related to the development of ACLF during 28-day follow-up. P-AD and ACLF-R scores were significantly superior to MELD, MELD-Na, CLIF-C ACLF and CLIF-C AD.

### **Research conclusions**

Serum sTREM-1 Level, P-AD and ACLF-R score will facilitate clinical decision-making in the management of patients with AD of cirrhosis.

### **Research perspectives**

A new approach to early diagnosis and treatment of patients with AD of cirrhosis.

### **ACKNOWLEDGEMENTS**

We thank the faculty and nurses contributed to this study, <sup>1</sup> the patients who participated in the study and their families.



# 10%

SIMILARITY INDEX

### PRIMARY SOURCES

- 1

Adrià Juanola, Isabel Graupera, Chiara Elia, Salvatore Piano et al. "Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis", Journal of Hepatology, 2021  
Crossref

120 words — 3%
- 2

[www.jci.org](http://www.jci.org)  
Internet

109 words — 3%
- 3

[www.researchgate.net](http://www.researchgate.net)  
Internet

45 words — 1%
- 4

Qun Cai, Mingyan Zhu, Jinnan Duan, Hao Wang, Jifang Sheng. "Establishment of prognostic scoring models for different etiologies of acute decompensation in hospitalized patients with cirrhosis", Journal of International Medical Research, 2019  
Crossref

31 words — 1%
- 5

Jasmohan S Bajaj, Richard Moreau, Patrick S Kamath, Hugo E. Vargas et al. "Acute-on-Chronic Liver Failure: Getting ready for prime-time", Hepatology, 2018  
Crossref

28 words — 1%
- 6

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)  
Internet

26 words — 1%

7	<a href="http://www.frontiersin.org">www.frontiersin.org</a> Internet	24 words — 1%
8	<a href="http://www.pubfacts.com">www.pubfacts.com</a> Internet	24 words — 1%
9	<a href="http://downloads.hindawi.com">downloads.hindawi.com</a> Internet	22 words — 1%

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	< 1%
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 10 WORDS